Safety and Efficacy of Human Chorionic Gonadotropin Hormone-Derivative EA-230 in Cardiac Surgery Patients: A Randomized Double-Blind Placebo-Controlled Study

What Was Tested

Researchers studied hCG (human chorionic gonadotropin) in this randomized controlled trial publication.

Cardiac surgery induces systemic inflammation and may impair renal function, affecting patient outcome.

Who Took Part

According to the abstract, 230 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, men only.

Collaboration of the Cardiothoracic Surgery, Anesthesiology, and the Intensive Care departments of a tertiary hospital in the Netherlands.

One hundred eighty patients undergoing an on-pump coronary artery bypass procedure with or without concomitant valve surgery.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this hCG (human chorionic gonadotropin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on hCG (human chorionic gonadotropin), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the hCG (human chorionic gonadotropin) group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Cardiotonic Agents, Coronary Artery Bypass, Coronary Artery Disease, Netherlands and Oligopeptides.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of hCG (human chorionic gonadotropin) in 230 patients.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Critical care medicine), a journal based in United States.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.